. A landmark study showed that the type, density and location of cytotoxic T cells within tumours enabled better prediction of patient survival than histopathological methods used for staging of cancers 1 . Strong infiltration of both the tumour centre and the invasive tumour margin by cytotoxic T cells (which express the CD8 surface marker) was shown to correlate with a favourable prognosis, regardless of the local extent of tumour invasion and spread to local lymph nodes. Conversely, weak in situ expansion of CD8 T cells correlated with a poor prognosis even in patients with minimal tumour invasion 1 . However, in the majority of patients this natural defence mechanism is severely blunted by immunosuppressive cell populations recruited to the tumour microenvironment, including regulatory T cells, immature myeloid cell populations and tumour-associated macrophages 4, [12] [13] [14] . Highly complex interactions among a variety of different cell types in the tumour microenvironment-including tumour cells, immune cells and stromal cells-therefore contribute to clinical outcome.
The critical role of T cells in immune-mediated control of cancers is further underscored by therapeutic benefit following administration of monoclonal antibodies targeting inhibitory receptors on T cells, CTLA-4 and PD-1 [15] [16] [17] [18] . Clinical benefit is enhanced by co-administration of antibodies targeting CTLA-4 and PD-1 19, 20 . Particularly notable is the finding that such antibodies can induce durable responses in a subset of patients with advanced disease. However, many of the regulatory pathways in T cells that result in loss of function within immunosuppressive tumour microenvironments remain unknown.
Immune cells perform complex surveillance functions throughout the body and interact with many different types of cells in distinct tissue microenvironments. Therapeutic targets for modulating immune responses are typically identified in vitro and tested in animal models at a late stage of the process. We postulated that the complex interactions of immune cells within tissues, many of which do not occur in vitro, offer untapped opportunities for therapeutic intervention. Here we have addressed the challenge of how targets for immune modulation can be systematically discovered in vivo.
Design of in vivo discovery approach
Pooled shRNA libraries have been shown to be powerful discovery tools [21] [22] [23] . We reasoned that shRNAs capable of restoring CD8 T-cell function can be systematically discovered in vivo by taking advantage of the extensive proliferative capacity of T cells following triggering of the TCR by a tumour-associated antigen. When introduced into T cells, only a small subset of shRNAs from a pool will restore T-cell proliferation, resulting in their enrichment within tumours. Over-representation of active shRNAs within a pool can be quantified by deep sequencing of the shRNA cassette from tumours and secondary lymphoid organs (Fig. 1a) .
We chose to study B16 melanoma, an aggressive tumour that is difficult to treat 24 . Melanoma cells expressed the surrogate tumour antigen ovalbumin (Ova), which is recognized by CD8 T cells from OT-I T-cell receptor transgenic mice 25, 26 . Initial experiments showed that such a screen could also be performed with pmel-1 T cells that recognize gp100, an endogenous melanoma antigen 27 , but the signal/noise ratio was lower for pmel-1 T cells owing to smaller T-cell populations in tumours. Naive T cells are difficult to infect with lentiviral vectors, and we therefore pretreated T cells for two days with the homeostatic cytokines IL-7 and IL-15 before spin infection with shRNA pools in a lentiviral vector. Successful transduction was monitored by surface expression of the Thy1.1 reporter (Extended Data Fig. 1a ). T cells were injected into B6 mice bearing day 14 B16-Ova tumours. Seven days later, T cells were purified from tumours and secondary lymphoid organs (spleen, tumour-draining and irrelevant lymph nodes) for isolation of genomic DNA, followed by PCR amplification of the shRNA cassette (Extended Data Fig. 1b) . The representation of shRNAs was then quantified in different tissues by Illumina sequencing.
In vivo shRNA pool screens
Two large screens were performed, with the first focusing on genes overexpressed in dysfunctional T cells (T-cell anergy or exhaustion; 255 genes, 1,275 shRNAs divided into two pools), and the second on kinases/phosphatases (1,307 genes, 6,535 shRNAs divided into seven pools) (Table 1a) . In these primary screens, each gene was represented by approximately five shRNAs (it is common that only one or two of such shRNAs have sufficient activity in pooled screens). We observed multiple distinct in vivo phenotypes. For certain genes, shRNAs were over-represented in all tested tissues compared to the starting T-cell population (for example, SHP-1), indicative of enhanced proliferation independent of TCR recognition of a tumour antigen. For other genes, there was a selective loss of shRNAs within tumours (for example, ZAP-70, a critical kinase in the T-cell activation pathway). We focused our analysis on genes whose shRNAs showed substantial over-representation in tumour but not spleen, a secondary lymphoid organ. Substantial T-cell accumulation in tumours was observed for a number of shRNAs, despite the immunosuppressive environment. For secondary screens, we created focused pools in which each candidate gene was represented by approximately 15 shRNAs. Primary data from this analysis are shown for three genes in Fig. 1b : LacZ (negative control), Cblb (an E3 ubiquitin ligase that induces T-cell receptor internalization) 28 and Ppp2r2d (not previously studied in T cells). For both Ppp2r2d and Cblb, five shRNAs were substantially increased in tumours (red) compared to spleen, whereas no enrichment was observed for LacZ shRNAs. Overall, 43 genes met the following criteria: $ fourfold enrichment for three or more shRNAs in tumours compared to spleen (Table 1a and Extended Data Fig. 1c, d ). The set included gene products previously identified as inhibitors of T-cell receptor signalling (including Cblb, Dgka, Dgkz, Ptpn2), as well as other well-known inhibitors of T-cell function (for example, Smad2, Socs1, Socs3, Egr2), validating our approach (Table 1b and Extended Data Table 1 ) [29] [30] [31] .
Target validation
We next confirmed at a cellular level that these shRNAs induce T-cell accumulation in tumours. OT-I T cells were infected with lentiviral vectors driving expression of a single shRNA and a reporter protein (Thy1.1 or one of four different fluorescent proteins), and after seven days the frequency of shRNA-transduced T cells was quantified in tumours, spleens and lymph nodes by flow cytometry. When the control LacZ shRNA was expressed in CD8 T cells, the frequency of shRNAexpressing CD8 T cells was lower in tumours compared to spleen (,twofold). In contrast, experimental shRNAs induced accumulation a, T-cell dysfunction and kinase/phosphatase screens. Listed are numbers of genes, shRNAs in each gene set and identified candidate genes. Genes were considered positive in secondary screens when $ 3 shRNAs showed $ fourfold enrichment in tumour relative to spleen. b, Functional classification of candidate genes from secondary screens.
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of CD8 T cells in tumours but not in the spleen (Fig. 2a and Extended Data Fig. 2a ). T-cell accumulation in tumours was more than tenfold relative to spleen for seven of these genes. The strongest phenotype was observed with shRNAs targeting Ppp2r2d, a regulatory subunit of the family of PP2A phosphatases 32 . A Ppp2r2d shRNA not only induced accumulation of OT-I CD8 T cells, but also CD4 T cells (from TRP-1 TCR transgenic mice) 33 , with T-cell numbers in tumours being significantly higher when Ppp2r2d rather than LacZ shRNA was expressed (36.3-fold for CD8; 16.2-fold for CD4 T cells) (Fig. 2b) . CD8 T-cell accumulation correlated with the degree of Ppp2r2d knockdown, and two Ppp2r2d shRNAs with the highest in vivo activity induced the lowest levels of Ppp2r2d messenger RNA (Extended Data Fig. 2b ). Ppp2r2d knockdown was also confirmed at the protein level using a quantitative mass spectrometry approach (Fig. 2e ). Ppp2r2d shRNA activity was specific because the phenotype was reversed when a Ppp2r2d complementary DNA (with wild-type protein sequence, but mutated DNA sequence at the shRNA binding site) was co-introduced with the Ppp2r2d shRNA ( Fig. 2c and Extended Data Fig. 3 ). Furthermore, OT-I CD8 T cells overexpressed Ppp2r2d in tumours compared to spleen (in the absence of any shRNA expression), indicating that it is an intrinsic component of the signalling network inhibiting T-cell function in tumours (Fig. 2d) . Microarray analysis of tumour-infiltrating T cells expressing different shRNAs showed that each shRNA induced a largely distinct set of gene expression changes, indicating that improved T-cell function in tumours can be mediated through a number of different intracellular pathways (Extended Data Fig. 4 ).
Cellular mechanisms for Ppp2r2d
We next examined the cellular mechanisms driving T-cell accumulation by a Ppp2r2d shRNA in tumours, specifically T-cell infiltration, proliferation and apoptosis. T-cell infiltration into tumours was assessed by transfer of OT-I CD8 T cells labelled with a cytosolic dye (carboxyfluorescein succinimidyl ester, CFSE). No differences were observed in the frequency of Ppp2r2d or LacZ shRNA-transduced CD8 T cells in tumours on day 1, indicating no substantial effect on T-cell infiltration (Fig. 3a) . However, analysis of later time points (days 3-7) demonstrated a higher degree of proliferation (based on CFSE dilution) by Ppp2r2d compared to LacZ shRNA-transduced T cells ( Fig. 3b and Extended Data Fig. 5a ). The action of Ppp2r2d was downstream of T-cell receptor activation because T-cell proliferation was enhanced in tumours and to a lesser extent in tumour-draining lymph nodes (Extended Data Fig. 5a ). In contrast, no proliferation was observed in irrelevant lymph nodes or the spleen where the relevant antigen was not presented to T cells (data not shown). Substantial T-cell proliferation was even observed for LacZ shRNA-transduced T cells (complete dilution of CFSE dye by day 7), despite the presence of small numbers of such cells in tumours. This indicated that LacZ shRNA-transduced T cells were lost by apoptosis. Indeed, a larger percentage of tumourinfiltrating T cells were labelled with an antibody specific for active caspase 3 when the LacZ control shRNA (rather than Ppp2r2d shRNA) was expressed ( Fig. 3c and Extended Data Fig. 5b ). Furthermore, coculture of CD8 T cells with B16-Ova tumour cells showed that the majority of LacZ shRNA-expressing T cells became apoptotic (65.7%), whereas most Ppp2r2d shRNA-transduced T cells were viable (89.5%, Fig. 3d ).
These results indicated the possibility that Ppp2r2d shRNA-transduced CD8 T cells may be able to proliferate and survive even when they recognize their antigen directly presented by B16-Ova tumour cells. This idea was tested by implantation of tumour cells into B2m 2/2 mice which are deficient in expression of MHC class I proteins 34 . In such mice, only tumour cells of the host, but not professional antigen-presenting cells, could present tumour antigens to T cells. Indeed, Ppp2r2d shRNAtransduced OT-I CD8 T cells showed massive accumulation within B16-Ova tumours in B2m 2/2 mice ( Fig. 3e ) whereas very small numbers of T cells were present in contralateral B16 tumours that lacked expression of the Ova antigen. Ppp2r2d-silenced T cells could therefore effectively proliferate and survive in response to tumour cells, despite a lack of suitable co-stimulatory signals and an inhibitory microenvironment.
Ex vivo analysis of tumour-infiltrating T cells at a single-cell level using a nanowell device 35, 36 also demonstrated that Ppp2r2d silencing increased cytokine production by T cells (Fig. 4a-c) . T cells were activated . e, Ppp2r2d protein quantification by mass spectrometry with labelled synthetic peptides (AQUA, ratio of endogenous to AQUA peptides). Representative data from two independent experiments (a-d); Two-sided student's t-test, *P # 0.05, **P # 0.01; mean 6 s.d.
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for 3 h by CD3/CD28 antibodies on lipid bilayers, followed by 1 h cytokine capture on antibody-coated slides. CD8 T cells showed a higher secretion rate for interferon-c, interleukin-2 and granulocyte-macrophage colony-stimulating factor (IFN-c, IL-2 and GM-CSF, respectively) and a larger fraction of T cells secreted more than one cytokine (Fig. 4b, c) . The presence of larger numbers of IFN-c-producing T cells was confirmed by intracellular cytokine staining ( Fig. 4d and Extended Data Fig. 5c ).
PP2A represents a family of phosphatase complexes composed of catalytic, scaffolding and regulatory subunits. Cellular localization and substrate specificity are determined by one of many regulatory subunits, of which Ppp2r2d is a member 32 . Ppp2r2d directs PP2A to Cdk1 substrates during interphase and anaphase; it thereby inhibits entry into mitosis and induces exit from mitosis 37 . PP2A also has a gatekeeper role for BAD-mediated apoptosis. Phosphorylated BAD is sequestered in its inactive form in the cytosol by 14-3-3, whereas dephosphorylated BAD is targeted to mitochondria where it causes cell death by binding Bcl-X L and Bcl-2 38 . PP2A phosphatases have also been shown to interact with the cytoplasmic domains of CD28 and CTLA-4 as well as Carma1 (upstream of the NF-kB pathway) 39, 40 , but it is not known which regulatory subunits are required for these activities. Anti-Ppp2r2d antibodies suitable for the required biochemical studies are not currently available.
Enhanced anti-tumour immunity
Finally, we assessed the ability of a Ppp2r2d shRNA to enhance the efficacy of adoptive T-cell therapy. B16-Ova tumour cells (2 3 10 5 ) were injected subcutaneously into B6 mice. On day 12, mice bearing tumours of similar size were divided into seven groups, either receiving no T cells, 2 3 10 6 shRNA-transduced TRP-1 CD4 T cells, 2 3 10 6 shRNA-infected OT-I CD8 T cells, or both CD4 and CD8 T cells (days 12 and 17). The modest anti-tumour activity of OT-I CD8 T cells (expressing the control LacZ shRNA) is consistent with published data 41 . Ppp2r2d-silencing improved the therapeutic activity of both CD4 and CD8 T cells (Fig. 5a, b) . A Ppp2r2d shRNA also enhanced anti-tumour responses when introduced into T cells specific for the endogenous melanoma antigens gp100 (pmel-1 CD8 T cells) and TRP-1 (TRP-1 CD4 T cells) (Fig. 5c ). gp100 is a relevant antigen in human melanoma, and a clinical trial in which a gp100-specific TCR (isolated from HLA-A2 transgenic mice) was introduced into peripheral blood T cells demonstrated therapeutic benefit in a subset of patients 42 .
Ppp2r2d-silenced T cells acquired an effector phenotype in tumours (Extended Data Fig. 6a ) and .30% of the cells expressed granzyme B (Extended Data Fig. 7a ). Consistent with greatly increased numbers of such effector T cells in tumours (Extended Data Fig. 7b ), terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) demonstrated increased apoptosis in tumours when Ppp2r2d rather than LacZ shRNA-expressing T cells were present (Extended Data Fig.  7c ). B16 melanomas are highly aggressive tumours in part because MHC class I expression is very low. Interestingly, Ppp2r2d but not LacZ shRNA-expressing T cells significantly increased MHC class I expression (H-2K b ) by tumour cells (Extended Data Fig. 7d) , possibly due to the observed increase in IFN-c secretion by T cells (Fig. 4b-d) . A 
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Ppp2r2d shRNA did not reduce expression of inhibitory PD-1 or LAG-3 receptors on tumour-infiltrating T cells, demonstrating that its mechanism of action is distinct from these known negative regulators of T-cell function (Extended Data Fig. 6b ). This finding suggests combination approaches targeting these intracellular and cell surface molecules.
Discussion
These results establish the feasibility of in vivo discovery of novel targets for immunotherapy in complex tissue microenvironments. We show that it is possible to discover genes with differential action across tissues, as exemplified by T-cell accumulation in tumours compared to secondary lymphoid organs. For genes with tissue-selective action, T-cell proliferation and survival are likely to be under the control of the T-cell receptor and therefore do not occur in tissues lacking presentation of a relevant antigen. Many variations of the approach presented here can be envisioned to investigate control of particular immune cell functions in vivo. For example, fluorescent reporters for expression of cytokines or cytotoxic molecules (granzyme B, perforin) could be integrated into our approach to discover genes that control critical T-cell effector functions in tumours.
Targeting of key regulatory switches may offer new approaches to modify the activity of T cells in cancer and other pathologies. For example, recent clinical trials have shown that transfer of genetically modified T cells can result in substantial anti-tumour activity [43] [44] [45] [46] . The efficacy of such T-cell-based therapies could be enhanced by shRNAmediated silencing of genes that inhibit T-cell function in the tumour microenvironment.
METHODS SUMMARY
In vivo shRNA screening. Nine shRNA pools (approximately 5 shRNAs per gene) were created and subcloned into the pLKO-Thy1.1 lentiviral vector. Each pool also included 85 negative-control shRNAs. OT-I T cells were cultured with IL-7 (5 ng ml 21 ) and IL-15 (100 ng ml 21 ); on day 2 cells were spin-infected with lentiviral pools supplemented with protamine sulphate (5 mg ml ) were isolated by flow cytometry from tumours, spleens, tumour-draining lymph nodes and irrelevant lymph nodes. Genomic DNA was purified (Qiagen) and deep-sequencing templates were generated by PCR amplification of the shRNA cassette. Representation of shRNAs in each pool was analysed by deep sequencing using an Illumina Genome Analyzer 47 . Secondary screens were performed using focused pools containing approximately 15 shRNAs per gene as well as 85 negative controls. Cut-off in the secondary screen was defined as $ 3 shRNAs with $ fourfold enrichment in tumour relative to spleen. Screening results were validated at a cellular level by introducing individual shRNAs into T cells, along with a reporter protein (green, teal, red or ametrine fluorescent proteins, Thy1.1). This approach enabled simultaneous testing of five shRNAs in an animal (three mice per group). Proliferation of shRNAtransduced T cells was visualized on the basis of CFSE dilution after 24 h as well as 3, 5 and 7 days.
12 15 18 21 24 27 30 33 36 39 42 45 12 15 18 21 24 27 30 33 36 39 42 45 ) were transferred (day 12 and 17) into mice bearing day 12 B16-Ova tumours. Tumour burden (a) and survival (b) were assessed. c, CD4
1 TRP-1 and CD8 1 pmel-1 T cells (3 3 10 6 each) were transferred (day 10 and 15) into mice with day 10 B16 tumours. Representative of two independent experiments (n 5 7-9 mice per group), survival analysed using log-rank (Mantel-Cox) test; mean 6 s.e.m. Author Information The access number for microarray data is GSE53388 in the Genomic Spatial Event (GSE) database. Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests: details are available in the online version of the paper. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to K.W.W. (kai_wucherpfennig@dfci.harvard.edu).
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per well) were spin-infected with lentiviral pools supplemented with protamine sulphate (5 mg ml were isolated by flow cytometry from tumours, spleens, tumour-draining lymph nodes and irrelevant lymph nodes. Genomic DNA was isolated (Qiagen) and deepsequencing templates were generated by PCR of the shRNA cassette. Representation of shRNAs in each pool was analysed by deep sequencing using an Illumina Genome Analyzer 47 . Data were normalized using the average reads of control shRNAs in each pool. Kinase/phosphatase genes were selected for the secondary screen based on expression levels in T cells (Immunological Genome Project, http://www.immgen. org/). For the secondary screen, approximately 10 additional shRNAs were synthesized for each gene (IDT) for a total of approximately 15 shRNAs per gene. These focused pools contained 85 negative-control shRNAs. Two control shRNAs (one for RFP, one for luciferase) showed some enrichment in tumours relative to spleen (4.0 and 5.1-fold, respectively). Cut-off in the secondary screen was defined as $ 3 shRNAs, with $ fourfold enrichment in tumours relative to spleen. Data from primary and secondary screens are provided in Supplementary Table 1 . T-cell isolation from tumours. B16-Ova melanomas were cut into small pieces in Petri dishes containing 5 ml of PBS, 2% FBS and washed with PBS. Tumours were resuspended in 15 ml RPMI supplemented with 2% FBS, 50 U ml 21 collagenase type IV (Invitrogen), 20 U ml 21 DNase (Roche); samples were incubated at 37 uC for 2 h, and tissue was further dissociated using a gentleMACS Dissociator (Miltenyi Biotech). Suspensions were washed three times with PBS and passed through a 70 mm strainer. Lymphocytes were isolated by density gradient centrifugation and then either analysed or sorted by flow cytometry using a FACSAria (BD Biosciences). Quantification of T-cell enrichment in tumours by flow cytometry. Individual shRNAs were cloned into lentiviral vectors encoding five different reporter proteins (GFP, teal fluorescent protein (TFP), RFP or ametrine fluorescent proteins, Thy1.1). Cytokine-pretreated OT-I T cells were transduced with lentiviral vectors driving expression of a single shRNA/reporter; 1 3 10 6 T cells of each population were mixed and co-injected intravenously into C57BL/6 mice bearing day 14 B16-Ova tumours. Seven days later, T-cell populations were identified by flow cytometry based on co-introduced reporters. Fold-enrichment in tumours compared to spleen was calculated based on the percentage of OT-I T cells in each organ expressing a particular reporter. In other experiments, 2 3 10 6 OT-I CD8 or TRP-1 CD4 T cells were transduced with lentiviral vectors encoding Ppp2r2d or LacZ shRNAs (Thy1.1 reporter) and injected into mice bearing day 14 B16-Ova (for OT-I T cells) or B16 (for TRP-1 T cells) tumours. On day 7, absolute numbers of shRNAexpressing T cells were determined in tumours and spleens. T-cell migration, proliferation and cytokine secretion. OT-I T cells expressing LacZ or Ppp2r2d shRNAs were purified using the Thy1.1 reporter and cultured in complete RPMI media without added cytokines for 24 h. Live cells isolated by Ficoll density gradient centrifugation (Sigma) were labelled with CFSE (carboxyfluorescein diacetate, succinimidyl ester, Invitrogen), and 2 3 10 6 labelled cells were injected into mice bearing day 14 B16-Ova tumours. CFSE dilution was quantified by flow cytometry at 24 h as well as days 3, 5 and 7 following transfer. In addition, intracellular staining was performed on days 3, 5 and 7 for IFN-c, TNF-a and isotype controls (BD). T-cell apoptosis. Cytokine pre-treated OT-I cells were transduced with LacZ or Ppp2r2d shRNAs and injected into mice bearing day 14 B16-Ova tumours. After 7 days, intracellular staining was performed using an activated caspase 3 antibody (Cell Signaling) and CD8/Thy1.1 double-positive T cells were gated in the FACS analysis. Treatment of tumours by adoptive T-cell transfer. B16-Ova cells (2 3 10 5 ) were injected subcutaneously into female C57BL/6 mice (10 weeks of age). On day 12, mice bearing tumours of similar size were divided into 7 groups (7-9 mice per group). Anti-CD3/CD28 bead activated CD4 TRP-1 or/and CD8 OT-I T cells infected with Ppp2r2d or LacZ shRNA vectors (2 3 10 6 T cells each) were injected intravenously on days 12 and day 17. For the treatment of B16 tumours, mice were treated at day 10 with anti-CD3/CD28 bead activated CD4 TRP-1 and CD8 pmel-1 T cells expressing Ppp2r2d or LacZ shRNAs (3x10 6 T cells each). Tumour size was measured every three days following transfer and calculated as length 3 width. Mice with tumours $ 20 mm on the longest axis were euthanized. Quantification of Ppp2r2d protein levels by mass spectrometry. A previously reported approach for absolute quantification (AQUA) of proteins from cell lysates by mass spectrometry was used to measure the effect of Ppp2r2d shRNA expression at the protein level 48 . This strategy was based on a 'selective reaction monitoring' approach in which a synthetic peptide with incorporated stable isotopes was used as an internal standard for mass spectrometry analysis. OT-I cells expressing LacZ or Ppp2r2d shRNAs were sorted to purity using FACS. Cells (1 3 10 6 ) were lysed in 1 ml of MPER extraction reagent (Pierce) containing a protease inhibitor cocktail (Sigma), 1 mM EDTA and 1 mM PMSF for 15 min on ice with occasional vortexing. Cell debris was removed by centrifugation and the protein supernatant was filtered (0.2-mm SpinX centrifuge filter, Costar). Protein concentration was determined by Bradford assay (Bio-Rad) and ultraviolet 280-nm analysis (NanoDrop instrument); 0.1 mg of cellular protein was separated by SDS-PAGE and stained with Coomassie blue reagent (Pierce). Gel bands corresponding to a MW range of 45-60 kDa were excised followed by in-gel digestion of proteins with trypsin. Eluted peptides were spiked with 300 fmol of isotopically labelled Ppp2r2d (FFEEPEDPSS [13C-15N-R]-OH) and Actin B (GYSFTTTAE[13C-15N-R]-OH) peptides (21 st Century Biochemicals) for quantification by LC-MS/MS (LTQ XL Orbitrap, Thermo Scientific). The Ppp2r2d peptide was chosen from a region of the protein that differs from other regulatory subunits of PP2A. Initially, a LC-MS/MS run of a LacZ shRNA sample was analysed to localize the Ppp2r2d and Actin B peptides that were being monitored. The AQUA peptides co-eluted with the corresponding endogenous peptides from the reverse-phase column, yet their higher molecular mass (10 Da) enabled the ratio of peak intensity for endogenous and AQUA peptides to be determined using abundant peptide fragment ions. Triplicate samples were analysed by SDS-PAGE followed by LC-MS/MS and statistical significance was determined using GraphPad Prism 6.0 software using a two-sided Student's t-test (F test, *P 5 0.0062). 
Vb5
1 T cells; transduced cells were detected based on expression of Thy1.1 or ametrine/GFP fluorescent reporters (representative data from 2 independent experiments, n 5 3 mice per experiment). c, qPCR analysis for Ppp2r2d expression in OT-I T cells transduced with LacZ shRNA, Ppp2r2d shRNA, and Ppp2r2d shRNA plus Ppp2r2d mutant cDNA. Data represent biological replicates (n 5 3), each value represents mean 6 s.d.
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